SAKK is suffering from a structural financial deficit that would lead to insolvency in the absence of radical corrective measures. SAKK has therefore introduced urgently needed actions.
SAKK decided a few years ago to expand, hence conducting more trials and increasing the number of patients involved. The number of activated trials has increased by 55% from 2015 to 2019. Many of the approved trials are academic and patient-oriented. SAKK overestimated the volume of funds it could raise from third parties to meet the financial requirements for these trials, resulting in a constantly growing deficit.
As a consequence, SAKK will have to drastically reduce its expenditures next year. It has drawn up a restructuring plan, which was approved by the SAKK Board on November 14, 2020. Among other things, the restructuring plan provides for cuts in the following areas: Reduction of payments to members (patient fees), reduction of trial activities (closure or suspension of trials) and reduction of staff at the SAKK Coordinating Center.
Only with immediate measures will SAKK succeed in finding the balance within a reasonable period, and to continue to advance research projects for the benefit of patients. By introducing these measures, SAKK will remain able to act in the future and continue to organize training at all levels. We are convinced that the measures to be taken will be effective and, if implemented consistently, will put SAKK back on the road to success. The SAKK Board expects to be back in the black no later than 2023. The prerequisite for this is that the implementation of restructuring measures is consistently continued until 2025.
If you have any further questions, please consult the FAQs on the financial situation at SAKK and its restructuring plan.
For further information please contact SAKK CEO PD Dr. Martin Reist: firstname.lastname@example.org.